Jeffrey W Sherman bought $10k of XERS
director at Xeris Biopharma Holdings, Inc.. 5,400 shares at an average of $1.87, traded Nov 27, 2023, filed Nov 29, 2023.
Score components
- +15RoleDirector
- 0Trade size$10k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context38% below the 52-week high
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001867096-23-000154, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 27, 2023 | POpen-market purchase Common Stockindirect: By: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001 | +5,400 | $1.87 | $10k | 5,400 | Nov 29, 2023 |
Related signals
Other insiders at Xeris Biopharma Holdings, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 21Weak | Xeris Biopharma Holdings, Inc. | Beth Hecht See Remarks | $157k 16,666 shares | -1% | |
| 21Weak | Xeris Biopharma Holdings, Inc. | Kevin McCulloch See Remarks | $141k 15,000 shares | -1% | |
| 16Weak | Xeris Biopharma Holdings, Inc. | Steven Pieper See Remarks | $47k 5,000 shares | -0% | |
| 23Weak | Xeris Biopharma Holdings, Inc. | Kevin McCulloch See Remarks | $250k 25,000 shares | -2% | |
| 21Weak | Xeris Biopharma Holdings, Inc. | Beth Hecht See Remarks | $141k 16,666 shares | -1% | |
| 21Weak | Xeris Biopharma Holdings, Inc. | Kevin McCulloch See Remarks | $127k 15,000 shares | -1% | |
| 16Weak | Xeris Biopharma Holdings, Inc. | Steven Pieper See Remarks | $43k 5,000 shares | -0% | |
| 16Weak | Xeris Biopharma Holdings, Inc. | Steven Pieper See Remarks | $43k 5,000 shares | -0% | |
| 21Weak | Xeris Biopharma Holdings, Inc. | Beth Hecht See Remarks | $134k 16,666 shares | -1% | |
| 20Weak | Xeris Biopharma Holdings, Inc. | Kevin McCulloch See Remarks | $120k 15,000 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.